[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Edinburgh\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":648},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,59,0,25,[9,57,85,111,136,164,191,215,235,262,282,308,329,354,379,404,427,457,483,507,530,554,585,605,624],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100623571","medical-phenotyping-of-nhs-general-adult-psychiatry-gap-inpatients-100623571",false,"NCT07398365","Medical Phenotyping of NHS General Adult Psychiatry (GAP) Inpatients","Inclusion:\n\n\\- Adults aged between 18 and 65 years admitted to GAP wards during recruitment period\n\nExclusion:\n\n\\- Admissions to non-GAP wards (e.g., forensic psychiatry, young people's units, perinatal, old age psychiatry, or general medical wards)","ALL","18 Years","65 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","This observational study will characterise the general psychiatric and general medical phenotypes of 100 adults, sequentially admitted to NHS General Adult Psychiatry (GAP) \"mental health\" inpatient wards, providing the first detailed information on morbidity in this patient population.",[25,26,27,28],"Bipolar Affective Disorder","Schizophrenia Disorders","Depression Disorders","Personality Disorders",[30,31,32,33,34,35,36,37,38,39,40,41,42,43],"General Adult Psychiatry","mental health","physical health","inpatients","schizophrenia","NHS","Bipolar affective disorder","depression","psychosis","treatment resistance","personality disorder","cardiometabolic disease","cancer","respiratory disease","RECRUITING","2026-06-30",{"date":47,"type":48},"2026-07-01","ACTUAL",{"date":50,"type":48},"2024-04-03",{"date":52,"type":21},"2026-12-31",{"name":54,"class":55},"University of Edinburgh","OTHER",1,{"id":58,"slug":59,"hasResults":12,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":16,"minAge":17,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":77,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":56},"100596664","intermittent-cold-exposure-and-brown-adipose-tissue-hyperplasia-100596664","NCT07048405","Intermittent Cold Exposure and Brown Adipose Tissue Hyperplasia","Investigating the Cellular Heterogeneity of Human Brown Adipose Tissue and Its (Patho)Physiological Regulation","ICEBATH","Inclusion Criteria:\n\n* Aged 18-40 years\n* Body mass index 18.5-25 kg\u002Fm2\n* Weight change of less than 5% in the past 6 months\n* No acute or chronic medical conditions\n* On no regular medications (other than contraceptives in female participants)\n* No claustrophobia\n* Alcohol intake ≤14 units\u002F week\n* Screening blood tests within acceptable limits (of no clinical significance)\n* Not currently pregnant, lactating or breastfeeding (female participants only)\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Not meeting inclusion criteria\n* Contra-indication to PET\u002FCT scan\n* Allergy to local anaesthetic",true,"40 Years",{"count":68,"type":21},12,"INTERVENTIONAL",[71],"NA","This clinical trial explores how repeated short-term cold exposure impacts the molecular and physiological function of brown adipose tissue (BAT), a thermogenic organ associated with improved cardiometabolic health. While intermittent cold exposure has been shown to increase BAT activity and mass, as measured by fluorodeoxyglucose (18F-FDG) uptake on positron emission tomography\u002Fcomputed tomography (PET\u002FCT) scans, the molecular adaptations within BAT and other thermogenic tissues including skeletal muscle and white adipose tissue (WAT) remain poorly understood.\n\nHealthy adults aged 18 to 40 years (6 males and 6 females) will participate in a 10-day cold acclimation protocol (2 hours per day using water-perfused cooling blankets). The primary objective is to determine how cold exposure alters cellular heterogeneity and gene expression in BAT, WAT, and skeletal muscle.\n\nParticipants will undergo baseline assessments, including measurements of energy expenditure, core and skin temperature, muscle activity, and blood sampling, each performed in both warm and cold conditions. These assessments will be followed by dynamic total-body PET\u002FCT imaging during cold exposure and tissue biopsies from BAT, subcutaneous WAT, and skeletal muscle. These procedures will be repeated after the cold acclimation protocol to evaluate physiological and molecular changes. Additional outcomes include changes in energy expenditure, cold tolerance, and immune cell responses induced by cold exposure.",[74,75,76],"Brown Adipose Tissue","Cold Exposure","18F-FDG PET\u002FCT",[74,75,76],"2026-06-29",{"date":45,"type":48},{"date":81,"type":48},"2025-05-01",{"date":83,"type":21},"2027-07",{"name":54,"class":55},{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":12,"sex":91,"minAge":92,"maxAge":4,"enrollmentInfo":93,"targetDuration":95,"studyType":22,"phases":4,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":56},"100611461","endo1000---a-uk-wide-endometriosis-research-project-100611461","NCT07240883","ENDO1000 - A UK-wide Endometriosis Research Project","INCLUSION CRITERIA\n\n1. Aged 16 or over\n2. Participants who confirm that they have received a clinical diagnosis of endometriosis (based on MRI, ultrasound or laparoscopy) within the last 10 years\n3. Living within the UK\n4. Willing and able to consent to installing and using the mobile ENDO1000 app on their smartphone or use our web-based equivalent.\n\nEXCLUSION CRITERIA\n\n1. Pregnant\n2. Known severe coagulation disorder\n3. Known active Hepatitis B\u002FC and\u002For HIV (due to Royal Mail restrictions on biospecimen postage)","FEMALE","16 Years",{"count":94,"type":21},1000,"2 Years","Approximately 1.5 million people in the UK, and 200 million globally live with endometriosis, and it is estimated to affect 1 in 10 women of reproductive age. Endometriosis is a chronic pain condition where the lining of the uterus (endometrium) grows in areas outside the uterus. This can cause patients a range of symptoms including severe pain, fatigue, irregular periods, infertility and gastrointestinal symptoms.\n\nThere is a clear unmet need for early diagnosis and more effective pain management for people who suffer from endometriosis. Endometriosis is a heterogeneous disease in terms of symptoms, trajectory, and indicated therapeutic course, which highlights the need to develop personalised\u002Ftargeted approaches for effective longitudinal management which are acceptable and accessible to patients and their health care team.\n\nThe goal of this study is to accelerate discovery and advance data-driven research into endometriosis diagnosis and treatment by collecting large, multimodal, longitudinal data.\n\nTo achieve this goal, the investigators plan to deliver a longitudinal cohort study. Approximately 3000 UK individuals with endometriosis will be invited over a 24-month period to self-report symptoms that include, pain, menstrual cycle, painkiller use, sleep, exercise, diet and bowel habits via a bespoke ENDO1000 mobile app. A cohort of 1000 women will be asked to complete more in-depth questionnaires asking about endometriosis history, quality of life and treatments. This cohort of women will be asked to take self-collected biological samples (blood, urine, saliva, vaginal swab and faeces). The investigators will look at, for example, inflammatory markers, examine the microbiome and may look at DNA, with permission to see if there are any markers that can help with diagnosis or treatment of endometriosis. At the same time participants will be asked to wear a smartwatch which will monitor, for example, temperature, ambient light, sleep patterns and movement. All this will help the investigators to build a picture over time of the participant's endometriosis symptoms, treatments and what may cause symptoms to flare which in turn could lead to more patient led treatments.",[98],"Endometriosis",[98,100,101,102],"Pelvic Pain","Longitudinal","Mobile app","2026-06-23",{"date":105,"type":48},"2026-06-24",{"date":107,"type":48},"2025-12-05",{"date":109,"type":21},"2030-12-31",{"name":54,"class":55},{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":12,"sex":16,"minAge":66,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":56},"100498896","quantitative-imaging-in-cardiac-transthyretin-amyloidosis-100498896","NCT05776212","Quantitative-imaging in Cardiac Transthyretin Amyloidosis","I-CARE","Inclusion Criteria:\n\n* Completion of informed consent\n* Age \\> 40 years for patients with ATTR or AL cardiac amyloidosis and age \\>30 years for patients with HCM\n* ATTR cardiac amyloid according to Expert Consensus Recommendations\n* AL amyloidosis according to Expert Consensus Recommendations\n* Hypertrophic cardiomyopathy according to European Society of Cardiology guidelines\n\nExclusion Criteria:\n\n* Inability or unwilling to give informed consent\n* Women who are pregnant, breastfeeding or of child-bearing potential (women who have experienced menarche, are pre-menopausal and have not been sterilised) will not be enrolled into the trial.\n* Renal dysfunction (eGFR ≤30 mL\u002Fmin\u002F1.73m2)\n* NYHA Class IV heart failure\n* Patients with atrial fibrillation and poor rate control.\n* Contraindications to MR\n* Previous history of contrast allergy of adverse reactions (gadolinium)\n* Contraindications to tafamidis therapy",{"count":119,"type":21},140,"Transthyretin amyloid cardiomyopathy (ATTR-CM), is a heart muscle disease that's stops the heart muscle working properly. With an ageing population, it is increasingly common but untreated, it has a poor prognosis. Several novel expensive treatments have become available, although we do not understand exactly how they work and why some patients respond, and others do not. The challenge is to develop better methods for monitoring the effects of these treatments, maximizing their benefits and cost-effectiveness. In I-CARE we aim to bring a new imaging technique, named 18F-fluoride PET, to the clinic and thereby improve the care of patients with ATTR-CM.\n\nHypotheses:\n\n1. A delayed imaging protocol and state-of-the-art PET motion correction will optimise 18F-fluoride imaging in ATTR-CM and provide a clear threshold in myocardial TBR values for the diagnosis of ATTR-CM.\n2. Optimised 18F-fluoride PET will provide a quantitative marker of the ATTR-CM burden that will allow disease progression and treatment response to be tracked.\n3. Myocardial 18F-fluoride TBR values will reduce in patients responding to tafamidis treatment and increase in non-responders and patients not receiving therapy",[122],"ATTR-CM",[124,125,126,127,128],"Amyloidosis","Heart failure","18F-fluoride positron emission tomography (PET)","Cardiovascular magnetic resonance (CMR)","Tafamidis",{"date":130,"type":48},"2026-06-26",{"date":132,"type":48},"2021-08-25",{"date":134,"type":21},"2026-09-30",{"name":54,"class":55},{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":65,"sex":16,"minAge":144,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":69,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":56},"100620932","pancreas-lipotoxicity-in-t2d-edinburgh-diabetes-remission-study-edrs-100620932","NCT07364045","Pancreas Lipotoxicity in T2D: Edinburgh Diabetes Remission Study (EDRS)","Mechanisms Mediating Reversible Lipotoxicity of the Pancreas in Obesity-induced Type 2 Diabetes: Edinburgh Diabetes Remission Study (EDRS)","EDRS","Inclusion Criteria:\n\n* Overweight\u002Fobese (BMI: 30-45 kg\u002Fm²) who have had T2D for less than 6 years or longer than 10 years, and are on treatment with diet alone or diet plus oral medication.\n* Overweight\u002Fobese (BMI: 30-45 kg\u002Fm²) who are at pre-diabetes stage, defined as fasting blood glucose 5.6-6.9 mmol\u002FL.\n* Overweight\u002Fobese (BMI: 30-45 kg\u002Fm²) who are non-diabetic (control group).\n* Age between 45 and 79 years inclusive.\n* Post-menopausal women only (to exclude sex hormone effects on lipid metabolism).\n* Good communication in English (able to give informed consent and follow dietary advice).\n* Willing and able to adhere to the study protocol, including dietary intervention and scheduled follow-up visits.\n\nExclusion Criteria:\n\n* Insulin therapy\n* HbA1c \\>12% (108 mmol\u002Fmol)\n* Weight loss \\>5 kg in last 6 months\n* Recent MI (within 6 months)\n* Known cancer in last 5 years\n* First-degree relatives of people with T2D (control group)\n* History of gestational diabetes\n* MRI contraindications (metal implants, claustrophobia)\n* Alcohol \\>14 units\u002Fweek\n* Advanced kidney or liver disease\n* Use of steroids or antipsychotics\n* Participation in another clinical trial\n* Life expectancy \\\u003C1 year\n* Allergy to local anaesthetic (for biopsy subgroup)\n* Any disorder that may jeopardise safety or compliance","45 Years","79 Years",{"count":147,"type":21},104,[71],"This study aims to investigate how fat accumulation in the pancreas contributes to the development of type 2 diabetes (T2D), and how weight loss may reverse this process. Previous research has shown that reducing body weight can lead to diabetes remission, and this was accompanied by lowering intrapancreatic fat and restoration of insulin secretion, but the mechanisms behind this are not fully understood. In particular, the study aims to unravel the role of hepatic de novo lipogenesis (DNL) and lipoprotein metabolism on pancreas lipotoxicity and beta cell recovery after weight loss.\n\nFour groups of participants will be recruited (n=26 per group): non-diabetic, pre-diabetic, short-duration T2D (\\\u003C6 years), and long-duration T2D (\\>10 years). Participants will be aged between 45 and 79 years and have a BMI between 30 and 45 kg\u002Fm². All participants will follow a structured weight loss programme using an 800 kcal\u002Fday Total Diet Replacement (TDR) for 8-12 weeks, followed by dietary support to maintain weight loss. The study is sponsored by NHS-Lothian and the University of Edinburgh and will be carried out at the Clinical Research Facility, Royal infirmary of Edinburgh by a specialist team (Senior Diabetes Research Nurse, Clinical Fellow, and Research Dietitian).\n\nThe primary endpoint of this study is to achieve a 10-15% reduction in body weight (\\~10 kg) through a low-calorie diet (800 kcal\u002Fday) to induce T2D remission and maintain this weight loss with structured dietary support for up to 6-12 months. The primary aim is to compare hepatic de novo lipogenesis-the conversion of sugar into fat by the liver-and lipoprotein export among the groups, and to examine how these parameters change in response to weight loss, improvement in metabolic status, and restoration of normal pancreatic function.\n\nSecondary endpoints include changes in weight, HbA1c, intraorgan fat (liver\u002Fpancreas), pancreas volume and tissue characteristics, beta cell mass and function (MRI\u002Fmixed meal test), circulating blood markers (i.e. lipids, exosomes, adipokines, and inflammatory markers), and the change in adipose tissue biology (fat biopsies).\n\nUltimately, this study aims to understand the mechanisms of T2D remission. It will help clarify the sequence of metabolic events leading to reversible pancreatic lipotoxicity and may inform the development of new, targeted therapies for T2D.",[151],"Type 2 Diabetes",[151,153,154,155],"Obesity","Remission","Weight loss","2026-06-17",{"date":158,"type":48},"2026-06-18",{"date":160,"type":48},"2026-06-15",{"date":162,"type":21},"2029-12-31",{"name":54,"class":55},{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":65,"sex":16,"minAge":171,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":56},"100613695","mapping-b-cell-biology-across-the-cardiovascular-territories-of-giant-cell-arteritis-towards-a-new-therapeutic-approach-rituximap-gca-100613695","NCT07269938","Mapping B-cell Biology Across the Cardiovascular Territories of Giant Cell Arteritis: Towards a New Therapeutic Approach (RituxiMAP GCA)","RituxiMAP GCA","Inclusion Criteria:\n\n* For GCA group:\n\n  1. Adults ≥ 50 years at the time of enrolment\n  2. Meets 2022 American College of Rheumatology\u002FEULAR classification criteria for giant cell arteritis\n  3. Imaging evidence of active LV-GCA in the previous 4 weeks\n  4. Will be managed with corticosteroid monotherapy by the standard care team.\n\nFor BCMID group:\n\n1. Adults ≥ 18 years at the time of enrolment\n2. Meets criteria for a diagnosis of a B-cell mediated immune disorder\n3. Considered to have active disease by referring team\n4. Will be managed as per standard of care by referring team\n\nFor AA group:\n\n1. Adults ≥ 50 years at the time of enrolment\n2. Imaging evidence of atherosclerotic aortic aneurysm\n\nExclusion Criteria:\n\n1. Participants receiving corticosteroids for \\>4 weeks immediately prior to baseline\n2. Previous diagnosis of GCA\n3. History of any major morbidity which the clinical investigator considers contraindicated to study entry\n4. Pregnancy or breastfeeding\n5. Advanced renal dysfunction (eGFR \\\u003C15ml\u002Fmin\u002F1.73m2)\n6. Patients without mental capacity or willingness to provide informed consent\n7. Inability or unwillingness to comply with the radiation protection advice","50 Years",{"count":173,"type":21},30,"B cells are a component of the immune system which appear be important in causing all forms of cardiovascular disease. Until now, it has not been possible to directly study these cells in living patients (essential to assess their potential as the target of new treatments). For the first time in any cardiovascular disease, this study will apply cutting edge scanning technology to visualise B cells in the blood vessels of giant cell arteritis (GCA) patients. GCA is a common and potentially deadly disorder of the blood vessels which is caused by abnormalities of the immune system. Current treatments are mainly limited to steroids. Unfortunately, these drugs bring tremendous side effects and so there is an urgent requirement to discover alternatives.\n\nLaboratory investigations tell us that B cells are highly present in GCA and so if the proposed scanning technology fails to identify these cells in the blood vessels of participants, then the technology is unlikely to be useful for other cardiovascular diseases. If, however, the study does successfully visualise B cells, this knowledge could pave the way for clinical trials of B cell targeted treatments (already established in other conditions) as steroid alternatives in GCA.\n\nThis study aims to map the distribution of the radiotracer zirconium-89 labelled rituximab within the blood vessels of patients with newly diagnosed GCA and compare this with two separate control groups without the condition. This will allow us to determine the role of B cells within this condition, and whether patients would benefit from B cell-depleting treatments such as rituximab.",[176],"Giant Cell Arteritis (GCA)",[178,179,180,181],"Giant cell arteritis","Vasculitis","Rituximab","PET scanning","NOT_YET_RECRUITING","2026-06-12",{"date":185,"type":48},"2026-06-16",{"date":187,"type":21},"2026-10",{"date":189,"type":21},"2029-06",{"name":54,"class":55},{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":212,"leadSponsor":214,"locationsCount":56},"100589183","mechanisms-of-myocardial-injury-and-ischemia-in-patients-with-rapid-atrial-fibrillation-100589183","NCT06951100","Mechanisms of Myocardial Injury and Ischemia in Patients With Rapid Atrial Fibrillation","Mi-AF","Inclusion Criteria:\n\n1. Age 18 years and over\n2. Primary presentation with symptoms related to atrial fibrillation\n3. Atrial fibrillation with a ventricular rate \\>100 bpm on a 12-lead electrocardiogram\n4. Able to provide informed consent\n\nExclusion Criteria\n\n1. Previous myocardial infarction\n2. Previous coronary revascularisation procedure\n3. Patients in renal failure (eGFR \\\u003C30ml\u002Fmin\u002F1.73m2) or major allergy to contrast media\n4. Pregnancy or breast feeding\n5. Deemed unsuitable for participation in the study by the attending clinician\n6. Previous enrolment in the trial",{"count":199,"type":21},300,"The goal of this observational study is to better understand the role of measuring troponin (a protein measured by a blood test) and coronary imaging in patients presenting with rapid atrial fibrillation (AF)\n\nThe main questions this study aims to answer are:\n\n1. Are patients with a fast, irregular heartbeat (rapid AF) and damage to the heart (myocardial injury) more likely than those without damage to the heart to have blocked heart arteries (obstructive coronary artery disease)\n2. Are patients with a fast, irregular heartbeat (rapid AF) and damage to the heart (myocardial injury) with further evidence that their heart hasn't been getting enough oxygen (myocardial ischemia) more likely to have imaging evidence of myocardial infarction than those without myocardial ischemia\n\nTo do this, we will measure troponin in patients with rapid AF and then carry out further investigations of the heart (electrocardiogram, echocardiogram, CT scan and cardiac MRI)",[202],"Atrial Fibrillation (AF)",[204,205,206,207,208,209],"Atrial Fibrillation","Cardiology","Emergency Medicine","Myocardial Infarction","Myocardial Ischemia","Coronary Artery Disease",{"date":160,"type":48},{"date":81,"type":48},{"date":213,"type":21},"2029-10",{"name":54,"class":55},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":229,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":4},"100583600","reducing-risk-of-stroke-and-dementia-in-patients-with-covert-cerebrovascular-disease-100583600","NCT06878430","Reducing Risk of Stroke and DementIa In patientS With COVert cERebrovascular Disease","Reducing Risk of Stroke and DementIa In patientS With COVert cERebrovascular Disease: a Pilot and Development Study","DISCOVER","Inclusion Criteria:\n\n* People who, at the time the letter is prepared or are identified by a clinician\n\n  * Age ≥ 65 years\n  * Have no known history of:\n\n    * Stroke or TIA\n    * Dementia\n    * Parkinson's disease\n    * Multiple sclerosis\n    * Metastatic cancer (or non-meningioma brain tumour).\n  * A CT or MRI scan report ≤5 years before study start date with of one or more of:\n\n    * Cerebral small vessel disease\n    * Deep old ischaemic stroke\n    * Cortical old ischaemic stroke\n\nExclusion Criteria:\n\n* Text of brain scan report unreadable\n* Do not consent to take part in study procedures\n* Unable to consent\n* Unable to communicate by email, letter or telephone through language, speech disability or lack of address\n* Unlikely to survive one year past enrolment in judgement of the study investigator",{"count":20,"type":21},"The purpose of the DISCOVER study is to pilot acceptable approaches to people with covert cerebrovascular disease (CCD) and their follow-up. This is the first step in designing efficient randomised trials of treatments to reduce the risk of stroke or dementia in people with CCD.",[226],"Covert Cerebrovascular Disease",[228],"ccd",{"date":185,"type":48},{"date":231,"type":21},"2026-08",{"date":233,"type":21},"2027-06",{"name":54,"class":55},{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":65,"sex":16,"minAge":17,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":261},"100496388","innate-immunity-in-copd-100496388","NCT05743582","Innate Immunity in COPD","Analysis of Innate Immune Competence in People With Chronic Obstructive Pulmonary Disease (COPD)","Inclusion Criteria:\n\nCOPD patients:\n\n* COPD patients aged 18-77 years who are GOLD Stage 1 or 2 or 3; for patients undergoing bronchoscopy already for a clinical reason.\n* COPD patients aged 18-77 years old who are GOLD Stage 1,2 or 3 for patients who are donating blood only.\n* COPD patients aged 18-69 years who are GOLD Stage 1 or 2 for patients undergoing bronchoscopy for research purposes.\n* COPD- Defined by radiological investigation of chest either chest X-ray or High-resolution CT scan in previous 12 months\n* Ability to provide informed consent\n\nHealthy volunteers:\n\n* Any healthy volunteer aged 18-77 years\n* Ability to provide informed consent\n\nExclusion Criteria:\n\nCOPD patients:\n\n* Individuals known to have active malignancy, immunosuppression, diabetes mellitus, chronic kidney disease or hepatic failure.\n* Individuals with a history of anaemia\n* Individuals who have donated \\>250 ml of blood for any reason within the last 6 months\n* Individuals who are pregnant or breast feeding.\n* Current participation in any other clinical trial, except those directly relating to this cohort and study.\n* Individuals who have had a febrile illness or other symptoms of acute infectious illness (respiratory, enteric or soft tissue) within the last 2 weeks\n* Individuals who have received a vaccine in the past 2 weeks\n* Inability to communicate in English or convey willingness to participate.\n* For bronchoscopy - Any significant lung condition that would contra-indicate bronchoscopy including:\n\nactive acute lung infection (with the exception of asymptomatic pulmonary colonisation) or malignancy, significant coexisting interstitial lung disease or additional pulmonary diagnosis in addition to COPD.\n\nHealthy volunteers:\n\n* Individuals known to have active malignancy, immunosuppression, diabetes mellitus, chronic kidney disease or hepatic failure\n* Individuals with anaemia on the screening full blood count (FBC)\n* Individuals who donated \\>250 ml of blood for any reason within the last 6 months\n* Individuals who are pregnant or breast feeding\n* Current participation in any other clinical trial\n* Individuals who have had a febrile illness or other symptoms of acute infectious illness (respiratory, enteric or soft tissue) within the last 2 weeks.\n* Individuals who have received a vaccine in the past 2 weeks\n* Chronic or acute respiratory disease.\n* Any chronic medical condition or receipt of regular prescription medication other than the oral contraceptive pill.\n* Inability to communicate in English or convey willingness to participate\n* For bronchoscopy - Any active lung condition including any lung infection or asthma Any significant abnormality on CXR that would contraindicate bronchoscopy FEV1 \\\u003C65% predicted (BTS Guidelines, 2001)","77 Years",{"count":244,"type":21},189,"Chronic Obstructive Pulmonary Disease (COPD) causes obstruction to airflow when breathing out. It is a leading cause of chronic lung disease, hospitalization and death. Smoking is the major cause of COPD but why some smokers develop COPD while others do not is poorly understood. A central feature of COPD is accumulation of inflammatory blood cells, macrophages and neutrophils, in the airway, leading to lung injury and airway damage. The small airways of many patients with COPD contain bacteria, which are absent in healthy smokers or non-smokers. These bacteria stimulate recruitment of neutrophils, macrophages and other inflammatory cells, further accelerating airway injury. The investigators and others have shown resident macrophages in the lung and inflammatory cells (neutrophils and macrophages) recruited from the blood, which normally clear bacteria, have reduced anti-bacterial capacity in COPD and that their altered function impairs the resolution of inflammation. The investigators now wish to test why these cells fail to clear bacteria focusing in particular on how they use molecules as food to generate energy, a process termed metabolism, since this is an important determinant of immune cell function. Comparison will be made between lung resident cells (obtained by performing bronchoscopy and washing a segment of lung to flush out immune cells) and those from the blood to determine if the alterations are specific to the lung. The investigators will identify alterations in responses to bacteria in relation to changes in metabolism . A major focus will be on how structures in the cell that normally are key for energy production (i.e. mitochondria) become dysfunctional and how this impacts responses to bacteria. The investigators will relate findings to the clinical features of COPD and to healthy non-smokers and smokers to separate smoking-related changes from COPD. The aim is to develop new approaches with which to treat and manage COPD.",[247],"Chronic Obstructive Pulmonary Disease",[249,250,251,252,253,254],"Alveolar macrophages","Peripheral blood mononuclear cells","Neutrophils","Bactericidal mechanisms","Immune cell metabolism","Epigenetics",{"date":185,"type":48},{"date":257,"type":48},"2023-05-11",{"date":259,"type":21},"2028-02-10",{"name":54,"class":55},2,{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":91,"minAge":268,"maxAge":144,"enrollmentInfo":269,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":56},"100547906","hpv-equity-study-exploring-cervical-cancer-control-in-scotland-for-women-with-experience-of-priority-risks-100547906","NCT06414057","HPV Equity Study: Exploring Cervical Cancer Control in Scotland for Women With Experience of Priority Risks","Inclusion Criteria:\n\nIndividuals will be eligible for participation in components 1 and\u002For 2 if they:\n\n* have a cervix\n* are aged 25-45 years (inclusive)\n* are able to provide informed consent for themself\n\nAnd have experience of either:\n\n* substance use\u002Faddiction\n* living in custodial settings\n* homelessness\n* involvement in transactional sex\n\nExclusion Criteria:\n\nIndividuals will be excluded from participation if they:\n\n* Do not have a cervix due to surgery or other reasons\n* Are known to have completed the full vaccination schedule (as per JCVI criteria for their age and immunocompetency) (Excluded from component 1 (vaccination and HPV screening) only - still able to participate in component 2 (individual interview))\n* Meet any of the vaccine exclusion criteria as set out in the local HPV PGD\n* Have had a confirmed anaphylactic reaction to a previous dose of HPV vaccine.\n* Have had a confirmed anaphylactic reaction to any component of the vaccine. Practitioners must check the marketing authorisation holder's SmPC for details of vaccine components.\n* Have a history of severe (i.e. anaphylactic reaction) to latex where the vaccine is not latex free.\n* Are known to be pregnant.\n* Are suffering from an acute severe febrile illness (the presence of a minor infection is not a contraindication for immunisation).\n\nAdditionally, PGDs advise caution where a neurological condition is believed to be progressing or there is neurological deterioration and therefore, individuals meeting this criteria will be excluded (from component 1 only).","25 Years",{"count":270,"type":21},500,"Individuals with experience of homelessness, substance use\u002Faddiction, transactional sex, and incarceration experience significant health inequities across a wide range of health conditions. This inequity includes cervical cancer with individuals in these populations less engaged with both routine human papillomavirus (HPV) vaccination and cervical cancer screening programmes, yet also at higher risk of developing cervical cancer.\n\nOpportunistic vaccination is recommended by the Joint Committee on Vaccination and Immunisation for 'other at risk\u002Fvulnerable groups' who may benefit (such as people with experience of transactional sex or incarceration) at clinical discretion. However, there is limited evidence on the feasibility, uptake, attitudes and impact of vaccination in these at-risk groups and no nationally funded programme.\n\nThis mixed methods exploratory study seeks to generate evidence to inform the optimal service design. Core objectives are to: 1) assess the feasibility and acceptability of offering opportunistic HPV vaccination during standard sexual health care to women at high risk of HPV and cervical cancer; 2) identify the type-specific prevalence of HPV among recruited participants; and 3) describe participants' perceptions and experiences of accessing routine HPV vaccination and cervical screening services, and\u002For this opportunistic (research) service.\n\nThe investigators will seek to recruit women with experience of homelessness, substance use\u002Faddiction, transactional sex, and incarceration. The study will include trans-men and non-binary people at risk of cervical cancer with the same risk experiences. Potential participants will be identified prospectively via attendance at specialist sexual health services in Scotland.\n\nParticipants will be offered HPV vaccination and testing, and\u002For an in-depth research interview. Participation can be completed within one clinic visit. The full vaccination course is available via participation (min\u002Fmax does spacing 6\u002F12 months) and participants testing positive for high-risk type HPV can\u002Fwill be followed up in full and supported in accessing treatment.",[273],"Human Papilloma Virus","2026-06-08",{"date":276,"type":48},"2026-06-09",{"date":278,"type":48},"2025-07-07",{"date":280,"type":21},"2027-10-31",{"name":54,"class":55},{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":69,"phases":291,"briefSummary":292,"conditions":293,"keywords":294,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":307},"100643011","sixth-generation-high-sensitivity-cardiac-troponin-t-for-the-early-rule-out-of-myocardial-infarction-a-controlled-before-and-after-study-100643011","NCT07636642","Sixth Generation High-sensitivity Cardiac Troponin T for the Early Rule Out of Myocardial Infarction: a Controlled Before and After Study","STEREO-MI","Inclusion Criteria:\n\n* Age 18 years and over.\n* Attending clinician suspects acute coronary syndrome.\n* At least one measurement of cardiac troponin using the Gen 5 or Gen 6 hs-cTnT assay.\n\nExclusion Criteria:\n\n* Insufficient clinical information to perform record linkage.\n* Not resident in Scotland.\n* Previous enrolment in the study.",{"count":290,"type":21},19500,[71],"Cardiac troponin is a protein released into the blood when the heart muscle is damaged. Measuring this protein helps doctors diagnose a heart attack (also called a myocardial infarction). Modern blood tests, known as high-sensitivity cardiac troponin assays, can detect very small amounts of this protein.\n\nA new version of this test, called Troponin T high-sensitivity Gen 6, has recently been developed and approved for use. It is designed to be more accurate and reliable, detecting smaller changes in troponin levels and being less affected by technical interference. The investigators believe this improved test will allow doctors to diagnose heart attacks more quickly and decide sooner who needs to stay in hospital and who can safely go home. This could help reduce overcrowding in Accident and Emergency (A\\&E) departments, a major challenge for the NHS.\n\nThis study will examine whether switching to this new test across a health board shortens the time patients with suspected heart attacks spend in the Emergency Department. The investigators will use information from the DataLoch Heart Disease Registry, which automatically collects anonymised hospital data for patients attending with possible heart attacks. The investigators will compare data from one year before and one year after implementation to see whether average length of stay changes and to confirm that patient safety remains high. This investigators will also measure both the current and new versions of the troponin test in surplus blood samples collected during two six-month periods-one before and one after the new test is introduced. This will allows the investigators to directly compare the two tests reliably.\n\nPatients will not need to do anything extra to take part - the study uses information and samples already collected as part of their usual care.",[207],[295,296,297,298,299],"cardiac troponin","myocardial infarction","acute coronary syndrome","accelerated decision pathway","Troponin T high sensitivity generation six","2026-06-04",{"date":276,"type":48},{"date":303,"type":21},"2026-06-01",{"date":305,"type":21},"2029-05",{"name":54,"class":55},3,{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":69,"phases":317,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":56},"100585521","developing-a-brief-intervention-to-communicate-cardiovascular-risk-to-patients-presenting-to-the-emergency-department-with-chest-pain-a-co-production-approach-phase-2-100585521","NCT06903442","Developing a Brief Intervention to Communicate Cardiovascular Risk to Patients Presenting to the Emergency Department With Chest Pain: a Co-Production Approach. Phase 2.","ACTION 2","Inclusion Criteria:\n\n* Patients who present to the Emergency Department with symptoms suggestive of acute coronary syndrome\n* A maximum high-sensitivity cardiac troponin I between 5 ng\u002FL and the sex-specific 99th centile.\n* Resides in Scotland and has a CHI number\n* Adults aged 18 and over\n* No history of cardiovascular disease\n* At least 1 modifiable cardiovascular risk factor: current smoker, hypertension (140\u002F90 mmHg), hypercholesterolaemia (\\>6.0 mmol\u002FL), overweight and obesity (BMI \\>25), hyperglycaemia or diabetes mellitus.\n* Patients who are able to provide informed consent\n\nExclusion Criteria:\n\n* Patients with a diagnosis of acute coronary syndrome during index presentation\n* Patients who are not able to give informed consent\n* Patients who do not speak English\n* Patients who are unable to attend hospital as outpatient to receive the cardiovascular brief intervention\n* Patients with ongoing or planned cardiovascular investigations or interventions\n* Patients with chronic kidney disease and a eGFR below 30 ml\u002Fmin",{"count":316,"type":21},118,[71],"Some patients who come to the emergency department with chest pain and have not had a heart attack, are at an increased risk of having a heart attack in the future. The investigators know this by taking a blood test (troponin) which looks at damage to the patient's heart.\n\nThese patients are often sent home from hospital with no information about their risk of heart disease. A patient survey revealed that patients in the emergency department would like to receive more information about heart disease.\n\nIn this study the investigators will provide patients who are at increased risk of cardiovascular disease with their troponin value. The investigators will deliver this information within a cardiovascular brief intervention, which is a short conversation with a patient about their health. In a previous study the investigators carried out some interviews with patients to find out how their results should be delivered and what information should be included in a cardiovascular brief intervention. The investigators also asked them the best way to provide patients with this information. The aim of this part of the study it to determine if the new cardiovascular brief intervention helps patients understand their risk and if it results in them making changes to their health.",[320],"Cardiovascular Diseases","2026-06-02",{"date":323,"type":48},"2026-06-03",{"date":325,"type":48},"2025-08-25",{"date":327,"type":21},"2027-03-30",{"name":54,"class":55},{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":91,"minAge":92,"maxAge":337,"enrollmentInfo":338,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":340,"conditions":341,"keywords":343,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":348,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":307},"100625065","point-of-care-tests-in-the-management-of-very-early-medical-abortion-100625065","NCT07417787","Point of Care Tests in the Management of Very Early Medical Abortion","Point of Care Testing for Human Chorionic Gonadotropin (HCG) to Improve Access to Very Early Medical Abortion and Simplify the Follow up Process","POCT VEMA","Inclusion Criteria:\n\n* Positive pregnancy test\n* Less than six weeks gestation based upon Last Menstrual Period (LMP)\n* No evidence of definite intrauterine pregnancy on ultrasound\n* No signs or symptoms or significant risk factors for ectopic\n* Wish to proceed to VEMA (Very Early Medical Abortion)\n* Available for usual clinical follow up\n* Willing to attend for serum Human Chorionic Gonadotropin (HCG) on two occasions Day 2-4 and Day 7 post mifepristone\n* Written informed consent\n\nExclusion Criteria:\n\n* Pain and\u002For bleeding\n* Significant risk factors for ectopic (previous ectopic, sterilisation, tubal disease, intrauterine device in situ)\n* Suspicious features for ectopic on ultrasound (adnexal mass, moderate free fluid)\n* Unable to provide blood sample\n* Lack of Capacity to consent","55 Years",{"count":339,"type":21},130,"This study will investigate the use of a point of care test in patients who are having an abortion at a gestation of \\\u003C6 weeks (known as a very early medical abortion). These patients have pregnancy hormone level checked at Day 0 and Day 7 to see if treatment has worked. The investigators plan to use a point of care test machine to see if it is possible to check pregnancy hormone level earlier than Day 7.",[342],"Abortion Early",[344,345,346,347],"VEMA","Very Early Medical Abortion","point of care test","POCT",{"date":323,"type":48},{"date":350,"type":48},"2026-04-23",{"date":352,"type":21},"2028-02",{"name":54,"class":55},{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":69,"phases":362,"briefSummary":363,"conditions":364,"keywords":367,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":375,"completionDateStruct":376,"leadSponsor":378,"locationsCount":56},"100626046","optimising-colorectal-cancer-patient-pathways-100626046","NCT07430540","Optimising Colorectal Cancer Patient Pathways","Optimising Patient Pathways for Earlier Detection of Colorectal Cancer in Secondary Care: Implementation of Multiple FIT Testing","Inclusion Criteria:\n\n* Patients referred to the NHS Lothian USoC CRC pathway or an urgent referral with 'red-flag' symptoms, and with a positive FIT on referral will be included.\n* Referred from start date of study, for up to 1 year\n\nExclusion Criteria:\n\n* Two negative FITs on referral\n* Patients referred with a palpable rectal or abdominal mass\n* Previous history of CRC or IBD, or under polyp surveillance\n* Known to have genetic hereditary condition predisposing patient to increased risk of CRC (e.g. Lynch, FAP, etc).",{"count":94,"type":21},[71],"Bowel cancer (colorectal cancer) is the 4th most common cancer in Scotland. Approximately 4,000 cases are diagnosed annually. Cancer-related deaths in Scotland are higher than other UK nations. Improving the early detection of bowel cancer, and therefore survival, is important.\n\nThe majority of bowel cancers are diagnosed within secondary-care (colorectal surgery unit). Upon GP referral to secondary-care, patients provide stool samples which are analysed for microscopic blood (FIT; faecal immunohistochemical test). Patients with a single positive result are more likely to have bowel cancer (0.2% risk if no blood detected, but 8.4% if detected). A positive test triggers further investigation, either CT scan or colonoscopy depending on the result. Currently, colonoscopy and radiology services throughout Scotland are under significant pressure causing delays.\n\nOnly 2% of patients referred to secondary-care are diagnosed with bowel cancer, and most colonoscopies performed do not yield significant findings. We have shown that performing two repeated FITs upon referral improves cancer pick-up rate (sensitivity) and reduces missed cancers. We successfully implemented this in NHS Lothian and contributed to national guidelines. Optimising allocation of investigations and therefore improving the detection-rate (specificity) may reduce colonoscopy demand, saving vital resources.\n\nNHS Lothian patients referred to secondary-care with symptoms concerning of bowel cancer will be included. \\~1,000 included patients will undertake extra FIT tests in study whether changes in stool blood levels over time help better allocate investigations and improve test specificity. With these results, a new secondary-care pathway will be designed. Health economic analysis will determine costs and benefits of implementing a new pathway and the risks of missed cancers. The project also provides infrastructure to collect additional stool and blood samples to develop new tests that improve bowel cancer detection.",[365,366],"Colorectal Cancer","Significant Bowel Pathology",[368,369,370,371,372],"colorectal cancer","Multiple testing","Diagnostic accuracy","Faecal Immunohistochemical Test","qFIT","2026-05-29",{"date":323,"type":48},{"date":45,"type":21},{"date":377,"type":21},"2037-03-22",{"name":54,"class":55},{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":16,"minAge":92,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":388,"conditions":389,"keywords":395,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":400,"completionDateStruct":401,"leadSponsor":403,"locationsCount":56},"100619169","use-of-a-novel-camera-to-check-the-bowel-after-polyp-or-tumour-removal-100619169","NCT07341126","Use of a Novel Camera to Check the Bowel After Polyp or Tumour Removal","Surveillance Digital Rectoscopy After Local Excision of Rectal Tumours","R-ALERT","Inclusion Criteria:\n\nAll participants who are capable of giving informed consent. All participants aged 16 years or over. All patients must have had a rectal tumour\u002F polyp removed within easy reach of the rigid sigmoidoscope.\n\nAll participants must be resident in the United Kingdom.\n\nExclusion Criteria:\n\nUnable to give informed consent. Under the age of 16 years",{"count":173,"type":21},"1.1 Polyps or tumours in the lower part of the bowel (rectum) can be removed using instruments inserted through the bottom which avoids major surgery and the possibility of a stoma bag (colostomy). Afterwards, it is important to check the area with regular camera tests. If checks are delayed, re-growths could be serious and may be untreatable. COVID and other factors have led to long waiting lists for camera checks and in NHS Lothian around 20% of all camera checks are done more than 6 months late.\n\nThe investigators want to try a new camera and approach that would allow us to reduce waiting lists. Using a short camera called a 'rectoscope' to check the lower bowel has already been shown to be safe, comfortable and acceptable to patients with other conditions. In fact, patients are unlikely to feel or realise any difference between the rectoscope and standard camera tests.\n\nThe investigators want to show that this 'rectoscope' can be safely used in the outpatient clinic with an enema (suppository) instead of strong bowel medicine taken by mouth the day before. This would mean the camera checks happen on time and would reduce waiting lists for other important tests.\n\nThe investigators will include 30 patients across three stages of our study. In the first set of patients, the investigators will use the rectoscope alongside the usual endoscope in the endoscopy room using the usual oral bowel medicine. This stage will check the rectoscope is acceptable to the patient and the doctor. In the next 10 patients the investigators will use a suppository instead of oral bowel medicine still using both cameras. Finally, the investigators will use the rectoscope in the outpatient clinic with an suppository to show this is an easy, effective and acceptable way to deliver timely camera checks.",[390,391,392,393,394],"Bowel Cancer","Polyp Rectal","Rectal Cancer","Rectal Adenocarcinoma","Rectal Adenoma",[396,397],"LumenEye","Rectoscopy","2026-05-28",{"date":373,"type":48},{"date":47,"type":21},{"date":402,"type":21},"2027-05-01",{"name":54,"class":55},{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":91,"minAge":17,"maxAge":412,"enrollmentInfo":413,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":414,"conditions":415,"keywords":416,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":56},"100633231","imaging-of-endometriosis-with-total-body-pet-ct-pet-endo-100633231","NCT07523997","Imaging of Endometriosis With Total-body PET-CT (PET-Endo)","Novel Non-invasive Imaging of Endometriosis Using Total-body PET-CT Programme (PET-Endo)","PET-Endo","Inclusion Criteria:\n\n* Chronic pelvic pain\n* Clinical\u002Fradiological diagnosis of likely endometriosis and due to undergo confirmatory laparoscopy in the subsequent four months\n\nExclusion Criteria:\n\n* Inability or unwilling to give informed consent\n* Actively trying to conceive, pregnant or breastfeeding\n* Post menopausal (no periods for \\>12 months and not taking hormonal treatments to prevent periods or bilateral oophorectomy performed)\n* Previous hysterectomy\n* Confirmed or suspected pelvic malignancy\n* Contraindication to MRI (ferromagnetic material in the body, metallic device implantation or claustrophobia)\n* Contraindication to buscopan (e.g. glaucoma, unstable cardiac disease, arrythmias, myasthenia, previous hypersensitivity to buscopan)\n* Taking part in a CTIMP or interventional non-CTIMP study\n* Previous severe pelvic inflammatory disease\n* Previous peritonitis","60 Years",{"count":173,"type":21},"Endometriosis is a disease that affects 1 in 10 women and is associated with debilitating pain and infertility. Endometriosis is where cells similar to those lining the womb (the 'endometrium') grow elsewhere in the body, forming 'lesions'. Most commonly the lesions grow on the lining of the pelvic cavity, called 'peritoneal' endometriosis. Lesions can also grow on the ovary, this is called 'ovarian' endometriosis, or form nodules, called 'deep' endometriosis.\n\nAt present the only way to confidently identify endometriosis is through surgery, this exposes patient to the risks of surgery and contributes to the diagnostic delay associated with endometriosis.\n\nPET\u002FCT is a specialist scan that is commonly used to identify cancers which cannot be seen on other types of scans. PET\u002FCT uses a 'tracer', a substance given into a vein which then temporarily accumulates in areas of disease.\n\nThis project will determine if a new specialist scan, total body PET\u002FCT, and novel tracers that were developed for other conditions can be used to identify some of the key pathways in endometriosis: bleeding and scarring. Being able to identify these processes in endometriosis lesions and being able to track how they change over time would improve our understanding of endometriosis. The investigators also want to know if these pathways are different between superficial, deep and ovarian endometriosis, and what the impact is of the hormones related to the menstrual cycle.\n\nIn this study up to 30 people who have suspected endometriosis and are already due to undergo diagnostic surgery will be asked to undergo two total-body PET\u002FCT scans in Edinburgh, one at one visit and one another visit. Participants will also have a PET\u002FMRI scan at visit. Participants will have a different tracer at each visit. The investigators will then compare the scan findings with their subsequent surgical findings.",[98],[98,417,418],"PET-CT","PET-MRI","2026-05-22",{"date":421,"type":48},"2026-05-27",{"date":423,"type":48},"2026-04-08",{"date":425,"type":21},"2027-12-31",{"name":54,"class":55},{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":69,"phases":436,"briefSummary":437,"conditions":438,"keywords":440,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":307},"100640756","pulmonary-rehabilitation-in-african-countries-100640756","NCT07602673","Pulmonary Rehabilitation in African Countries","Respiratory Medicine and Pulmonary Rehabilitation Feasibility Study and Randomised Controlled Trial in Nigeria, South Africa and Cameroon","Inclusion Criteria:\n\n* Male and female adults (\\>= 18 years) with specified clinical diagnosis (typically by detailed clinical history \\[persistent symptoms for ≥6 months\\] plus spirometry and\u002For other available tests, e.g., chest X-ray\\]\n* Individuals with CRDs, specifically COPD, asthma or post-tuberculosis lung disorder\n* Patients with CRDs who have an indication for PR (specifically, these are patients with moderate to severe staged disease who present with reduced exercise\u002Ffunctional capacity, poor quality of life, high disease symptoms, particularly dyspnea) and are medically fit to undergo exercise training (which is to be determined by pre-exercise screening and field tests).\n* Patients with CRDs attending regular follow-up in the respiratory clinics of the selected centres.\n* Patients who are willing and able to provide written or oral (audio recorded) informed consent\n* All levels (primary, secondary, and tertiary) of healthcare professionals, including doctors, nurses, physiotherapists, respiratory therapists, medical assistants, healthcare administrators, pulmonologists, and other formal practitioners working in primary, secondary, and tertiary care settings, who provide services to patients who may potentially require PR.\n* Relevant stakeholders, including policymakers, religious leaders, sports leaders, the pharmaceutical industry, social workers, managers, and hospital\u002Fpractice owners.\n* Willing and able to provide written or oral (audio recorded) informed consent.\n\nExclusion Criteria:\n\n* Patients with other significant chronic co-morbidities such as heart failure, ischemic heart disease, DM, and confusion\u002Fdementia\n* Pregnant women\n* Co-morbidity that is a contraindication to PR (e.g., unstable angina, aortic aneurysm, recent myocardial infarction, acute infection, etc.)\n* Significant cognitive or physical impairment preventing participation in PR\n* Active pulmonary tuberculosis vi. Patient with current or recent disease exacerbations\n* Non-respiratory cause for symptoms (e.g., breathlessness due to heart failure, anaemia)\n* Unable to participate in exercise (e.g., due to severe arthritis or paralysis)\n* Undertaken PR within one year.\n* Unwilling to participate in the study.\n* Unable to give written or oral (audio recorded) informed consent\n* Healthcare professionals who are not involved in the care of patients who require PR, e.g., midwives\n* Having a conflict of interest that may influence the outcome\n* Unable and unwilling to give written or oral (audio recorded) informed consent",{"count":435,"type":21},150,[71],"Chronic Respiratory Diseases (CRDs) are common disabling conditions worldwide with high prevalence, morbidity and mortality. More than half of the CRD patients live in low- and middle-income countries (LMICs) where resources for identifying the condition, understanding the disease status of individual patients, and overall management are often poor. CRDs in high-income countries (HICs) are dominated by chronic obstructive pulmonary disease (COPD) and asthma, whereas in LMICs, post-tuberculosis (TB) lung disorders, bronchiectasis, and other (often unidentified) respiratory conditions contribute to a significant proportion of CRDs. Pulmonary rehabilitation (PR) is an essential component of evidence-based clinical management guidelines for CRDs, though most of the evidence on PR is disease-specific and generated from HICs. A recent systematic review by the RESPIRE group, with whom we collaborate, revealed that 12 out of 13 studies suggested that PR for patients with CRDs in LMICs was an effective intervention, though the studies were typically at high risk of bias. This highlighted the need for further high-quality large-scale studies in LMICs to assess the enablers and barriers, effectiveness, components, and mode of delivery of PR for CRDs.\n\nIn this feasibility study, the investigators will assess the resource infrastructure, optimal components of the PR programme, relevant CRDs eligibility, and model of service delivery for providing PR in Nigeria, South Africa and Cameroon, and then conduct a pilot randomised controlled trial (RCT). The investigators will also assess potential outcomes, including before and after intervention measurement of functional exercise capacity and relevant patient-reported outcomes. In qualitative interviews, the investigators will explore the barriers and enablers and stakeholders' opinions on implementing PR in each country.\n\nThe investigators will recruit (Nigeria - 30, South Africa - 30 and Cameroon - 30) clinically eligible patients and provide them with 8 weeks of either a centre- or community-based PR incorporating components derived from global PR guidelines and informed by the prior RESPIRE's systematic review and adapted to be deliverable in a low-resource setting. The investigators will assess the patients at baseline, end of the program (8 weeks) and then at 6 months follow-up to assess sustainability. Moreover, along with the quantitative assessment of outcomes (functional exercise capacity, health-related quality of life, dyspnoea severity and other secondary parameters), the investigators will conduct a qualitative interview with a purposive sample of patients, providers, and other health care professionals, e.g., GPs, pulmonologists, physiotherapists. The investigators will synthesise the findings for conference presentations, peer review publications, and advocate for PR with stakeholders.",[439],"Chronic Respiratory Conditions",[441,442,443,444,445,446,447,448,449],"COPD","Asthma","Tuberculosis","Chronic Respiratory Diseases","Africa","Nigeria","South Africa","Cameroon","Pulmonary Rehabilitation","2026-05-18",{"date":419,"type":48},{"date":453,"type":21},"2026-09-01",{"date":455,"type":21},"2027-12-01",{"name":54,"class":55},{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":12,"sex":91,"minAge":92,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":69,"phases":466,"briefSummary":467,"conditions":468,"keywords":469,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":56},"100639455","whole-body-cryotherapy-as-a-non-pharmacological-treatment-to-reduce-chronic-pelvic-pain-and-improve-quality-of-life-in-people-with-endometriosis-100639455","NCT07603960","Whole-Body Cryotherapy as a Non-Pharmacological Treatment to Reduce Chronic Pelvic Pain and Improve Quality of Life in People With Endometriosis","An Exploratory Clinical Trial to Determine the Impact of Whole-body Cryotherapy on Endometriosis-associated Pain","CHILL-Endo","Inclusion Criteria:\n\n* Women or assigned female at birth\n* Aged 16 or over\n* Endometriosis identified at laparoscopy or imaging, performed within the last ten years\n* Chronic pelvic pain for more than six months\n* Willing to comply with the treatment\n* Willing to use effective contraception throughout the trial (if needed)\n* Willing and able to give informed consent\n\nExclusion Criteria:\n\n* Pregnant, breastfeeding or actively trying to get pregnant\n* Post-menopausal (no periods for \\>12 months and not taking hormonal treatments to prevent periods, or bilateral oophorectomy performed)\n* Previous hysterectomy with bilateral oophorectomy\n* Raynaud's Disease\n* Current treatment for malignancy\n* Diabetes\n* Known hypothyroidism\n* Pre-existing or current diagnosis of anaemia\n* Cardiovascular disease: severe hypertension (180\u002F100, unstable angina, arrhythmia, recent (\\\u003C6months) myocardial infarction, peripheral artery disease, cardiac pacemaker, recent (\\\u003C6months) stroke or transient ischaemic attack)\n* Acute kidney and urinary tract diseases\n* Cryoglobulinemia\n* Previous venous thromboembolism or peripheral artery occlusive disease\n* Cold urticaria\n* Livedo reticularis\n* Open wounds or ulcers, large-area bacterial and viral skin infections\n* Uncontrolled seizure disorder\n* Known coagulopathy (eg von Willibrand disease, haemophilia)\n* Severe claustrophobia\n* Acute infections and fever\n* Intoxication (alcohol, drugs)\n* Signs or symptoms of cold allergy\n* Severe wasting diseases\n* Known Hepatitis B\u002FC and\u002For HIV (due to Royal Mail restrictions on biospecimen postage)",{"count":173,"type":21},[71],"The aim of this study is to investigate whether whole-body cryotherapy (a brief exposure to very cold temperatures) can help reduce pain and improve quality of life in people living with endometriosis, and whether it may represent a safe, non-pharmacological approach to managing endometriosis-related symptoms.\n\nUp to 30 participants with symptomatic endometriosis (chronic pelvic pain for more than six months) will be recruited over a 12-month period. Participants will attend two study visits at the hospital, approximately four weeks apart. Between these visits, participants will undergo five whole-body cryotherapy sessions, each lasting approximately 3 minutes. During cryotherapy, participants stand in a specialised chamber where the body is briefly exposed to cold, dry air (around -120°C).\n\nDuring the study, will be assessed changes in systemic inflammation and biological markers using blood, saliva, urine, vaginal, and stool samples. Data will be collected using questionnaires evaluating pain and related symptoms, quality of life, sleep, fatigue, intestinal symptoms, and overall wellbeing.\n\nThe active study phase lasts approximately 4-6 weeks. A final follow-up assessment at 15 weeks will be conducted remotely using questionnaires and self-collected samples.",[98],[470,471,472,473,474,475],"endometriosis","cryotherapy","inflammation","pain","chronic pelvic pain","endometriosis-associated pain","2026-05-15",{"date":419,"type":48},{"date":479,"type":48},"2026-04-09",{"date":481,"type":21},"2027-05-31",{"name":54,"class":55},{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":69,"phases":491,"briefSummary":492,"conditions":493,"keywords":495,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":56},"100608120","the-use-of-robot-assisted-magnetically-controlled-capsule-endoscopy-in-patients-with-iron-deficiency-anaemia-100608120","NCT07197424","The Use of Robot Assisted Magnetically Controlled Capsule Endoscopy in Patients With Iron Deficiency Anaemia","Robot Assisted Magnetically Controlled Capsule Endoscopy","Inclusion Criteria:\n\n* Adult patients aged 18 and above\n* Confirmed diagnosis of iron deficiency anaemia (either recent onset or recurrent)\n* No significant cause for iron deficiency anaemia previously identified on upper GI endoscopy, colonoscopy or CT colonography\n* Patients who would either have proceeded directly to small bowel capsule endoscopy (SBCE) or who would have had an initial 'watch and wait' period prior to undergoing SBCE\n\nExclusion Criteria:\n\n* Known or suspected gastrointestinal obstruction, strictures or fistulae\n* Previous abdominal surgery\n* Dysphagia\n* Patients with a pacemaker, defibrillator or other implanted electronic device\n* In vivo retention with medical metal fittings - shunts, plates, stents or clips\n* A history of metal fragments in the eyes or elsewhere in the body\n* Confirmed or possible pregnancy\n* Patients who are not deemed to have capacity according to the Adults with Incapacity Act\n* Patients who are currently part of another research study",{"count":20,"type":21},[71],"In this study the investigators will recruit patients who have already had an upper gastrointestinal (GI) tract endoscopy (OGD) and lower GI tract investigations which did not identify the source of iron deficiency anaemia, and who need the small bowel to be investigated. This will comprise both patients who would have proceeded directly to small bowel capsule endoscopy (SBCE) under standard care and also those from whom an initial 'watch and wait' approach may have been adopted before proceeding to SBCE. The investigators propose to investigate these patients during a single patient visit to Leith Community Treatment Centre, Edinburgh, Scotland, with a CE marked robotic capsule system which can examine both the upper GI tract (i.e. the oesophagus and the stomach) and the small bowel in one investigation using a magnetic guided capsule.\n\nThe aim of the study is to compare the findings from OGD with the robotic capsule system and to determine if such a system may safely replace OGD - thus examining the upper GI tract and small bowel for IDA in one less invasive investigation. This has the potential to decrease patient discomfort, stress and anxiety, while also reducing pressure on busy endoscopy departments, helping to ensure that the right patients receive the right investigations in a timely manner.",[494],"Iron Deficiency Anaemia",[496,497,498],"capsule endoscopy","robot assisted magnetically controlled capsule endoscopy","iron deficiency anaemia","2026-05-13",{"date":501,"type":48},"2026-05-14",{"date":503,"type":48},"2026-05-11",{"date":505,"type":21},"2027-03",{"name":54,"class":55},{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":65,"sex":16,"minAge":17,"maxAge":514,"enrollmentInfo":515,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":516,"conditions":517,"keywords":521,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":56},"100219340","optical-coherence-tomography-and-nephropathy-the-octane-study-100219340","NCT02132741","Optical Coherence Tomography And NEphropathy: The OCTANE Study","Assessment of Retinal Vasculature Using Optical Coherence Tomography in Health, Hypertension & Chronic Kidney Disease.","Inclusion Criteria:\n\n* Male or female\n* Age 18-80\n* Body mass index ≤35\n* For those with hypertension: BP ≥140\u002F90 or on treatment for hypertension\n* For those with CKD: CKD as defined by the Kidney Diseases Quality Initiative guidelines\n\nExclusion Criteria:\n\n* Subject is below the age of legal consent, or is mentally or legally incapacitated\n* The subject has donated blood (450 ml) within the last 4 weeks\n* Past or present drug or alcohol abuse including intravenous drug abuse at any time\n* Participation in another clinical trial within 1 month\n* Considered to be at high risk of HIV or hepatitis B\n* Patients with known eye disease, or previous eye surgery, or refractive error greater than +\u002F- 6 dioptres.","80 Years",{"count":435,"type":21},"Patients with high blood pressure (hypertension) and chronic kidney disease are at an increased risk of developing heart disease and strokes. Part of this risk is due to changes in the structure and function of the blood vessels throughout the body. It is thought that reducing high blood pressure and treating chronic kidney disease improves the structure and function of blood vessels but information on this is limited. Optical coherence tomography (OCT) is a method of looking at the blood vessels at the back of the eye. It is a simple, quick and non-invasive test that you may have previously had during a visit to the optician. The purpose of the study is to ascertain whether OCT is able to detect changes in the eye's blood vessels in patients with hypertension and chronic kidney disease compared to healthy individuals and also to see if any differences seen improve with treatment.",[518,519,520],"Health","Hypertension","Chronic Kidney Disease",[522],"OCT; hypertension; CKD","2026-05-08",{"date":499,"type":48},{"date":526,"type":48},"2014-05-16",{"date":528,"type":21},"2028-09",{"name":54,"class":55},{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":536,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":539,"conditions":540,"keywords":542,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":56},"100637140","administering-atropine-through-autoinjectors-within-ambulance-services-for-poisoning-patients-in-sri-lankas-north-central-province-100637140","NCT07581301","Administering Atropine Through Autoinjectors Within Ambulance Services for Poisoning Patients in Sri Lanka's North Central Province","Feasibility of Using Ambulance Services to Administer Atropine Using Autoinjectors in Farming Communities in the North Central Province, Sri Lanka","FAST-AID","Inclusion Criteria:\n\n* Participants over the age of 18 who are willing and able to provide written informed consent will be asked to participate in the study.\n* Ambulance staff directly involved in the management and response to pesticide poisoning cases during the intervention period in the selected two geographical clusters.\n* Doctors and nurses from selected hospitals in the two geographical clusters who managed pesticide poisoning patients that received atropine via autoinjectors administered by ambulance staff during the intervention period.\n* Pesticide poisoning patients managed by Suwa Seriya ambulances in the selected two geographical clusters of the Anuradhapura district during the intervention period.\n\nExclusion Criteria:\n\n* Participants who are unwilling or unable to provide written informed consent will not be included in the study.\n* Participants who do not speak Sinhala.\n* Participants under the age of 18 years.",{"count":173,"type":21},"Pesticide poisoning remains one of the most serious public health challenges in rural Sri Lanka, particularly in the North Central Province (NCP), where intensive farming and heavy pesticide use have led to high rates of accidental and intentional poisoning. Although the antidote, atropine, is routinely used in hospitals, delays in receiving treatment often occur because patients must travel long distances before reaching care. Early initiation of treatment is critical, and survival depends on the speed with which atropine is administered.\n\nThe government's free 1990 Suwa Seriya ambulance service, established in 2016, provides emergency transport across Sri Lanka but currently has limited capacity for administering time-sensitive antidotes. Community consultations conducted during an earlier study revealed that people preferred life-saving treatments such as atropine to be managed through the formal health system, rather than stored in villages. This led to the idea of exploring whether ambulance staff could safely use atropine autoinjectors; simple, pre-filled devices that deliver the drug quickly and can safely be used even by non-medical professionals.\n\nThe FAST-AID study aims to assess the feasibility of introducing atropine autoinjectors into Sri Lanka's emergency ambulance system for use in pesticide poisoning cases. The main question is:\n\nHow feasible is it to integrate atropine autoinjectors into the ambulance service to provide earlier treatment for pesticide poisoning patients? Secondary questions explore (1) how ambulance coverage and travel routes affect timely administration; (2) how ambulance and hospital staff experience the use of the devices; and (3) how patients perceive the care they received.\n\nThe study will be carried out in the Anuradhapura District of the NCP, in collaboration with the Suwa Seriya ambulance service and selected hospitals. Two geographical clusters, one densely populated and one more remote, have been chosen to compare different service conditions. Around 30 pesticide poisoning patients will receive atropine using autoinjectors during ambulance transport, under guidance from an on-call emergency physician.\n\nData will be collected through several complementary methods:\n\n* Operational data from ambulance and hospital records (e.g., response times, use of autoinjectors, patient outcomes).\n* Geographic mapping (GIS) of ambulance coverage to assess accessibility and response patterns.\n* Focus group discussions with ambulance and hospital staff to explore training, practical challenges, and perceptions of the intervention.\n* Semi-structured interviews with patients to understand their lived experience of emergency care.\n* Participant observation in ambulances and hospitals to capture the everyday realities of emergency response.\n\nParticipants will be adults (aged 18 or above) who either work in the ambulance or hospital system or who have experienced pesticide poisoning and received atropine during the study period. All participants will provide written informed consent.\n\nThe research team will include Sri Lankan and UK collaborators from the University of Edinburgh and the South Asian Clinical Toxicology Research Collaboration (SACTRC).\n\nBy assessing the operational and social feasibility of using atropine autoinjectors in ambulances, this study aims to strengthen Sri Lanka's emergency response system and provide a foundation for a larger trial that could ultimately help save lives of those experiencing pesticide poisoning.",[541],"Pesticide Poisoning",[541,543,544,545],"Pre-Hospital Care","Atropine","Autoinjectors","2026-05-06",{"date":548,"type":48},"2026-05-12",{"date":550,"type":21},"2026-08-01",{"date":552,"type":21},"2027-02-01",{"name":54,"class":55},{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":558,"acronym":559,"eligibilityCriteria":560,"healthyVolunteers":65,"sex":16,"minAge":561,"maxAge":4,"enrollmentInfo":562,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":564,"conditions":565,"keywords":572,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":581,"completionDateStruct":582,"leadSponsor":584,"locationsCount":56},"100629097","cognitive-assessment-and-post-operative-complications-after-surgery-linking-anaesthesia-and-risk-100629097","NCT07470216","Cognitive Assessment And Post-Operative Complications After Surgery: Linking Anaesthesia And Risk","CAPSULAR","Inclusion Criteria:\n\n* Age ≥ 70\n* Seen in the Perioperative medicine for Older People undergoing Surgery (POPS) clinic\n* Scheduled for colorectal or urological surgery with expected anaesthesia time over 60 minutes\n\nExclusion Criteria:\n\n* Regional anaesthesia only\n* Planned day surgery or expected hospital stay \\\u003C 24 hours\n* Expected to remain sedated and ventilated for \\> 24 hours postoperatively\n* Participant does not wish to remain in the study if capacity is lost during the study\n\nCO-ENROLMENT\n\n* As this is a non-intervention study, co-enrolment will be permitted in other studies that do not conflict with this protocol.","70 Years",{"count":563,"type":21},40,"Many older people can experience confusion, memory problems, or a decline in their thinking after major surgery. These problems are sometimes called 'postoperative neurocognitive disorders' or PND and can affect recovery and a person's ability to live independently.\n\nThe investigators want to find out the best way to study these problems in older patients undergoing surgery. This is a 'feasibility study', which means we are testing the research methods. The investigators want to see if it is possible to ask participants to do memory tests and give blood samples before and after their operation. The investigators are hoping to include around 40 patients over 2 years in this study.\n\nThe investigators will compare performance in memory (cognitive assessment) findings before and after surgery and link this to data taken from the anaesthetic, including the types of drugs used, duration, brain features from processed electroencephalogram monitoring and standard recommended monitoring. In addition the investigators will link this to blood sample markers of brain health and function (biomarkers).\n\nThe results of this study will help the investigators plan a much larger study in the future, with the ultimate goal of making surgery safer for the brain.",[566,567,568,569,570,571],"Cognitive Impairment","Cognitive Impairment, Mild","Cognitive Impairment, Progressive","Anesthesia","Anesthesia Brain Monitoring","Anesthesia Depth Monitoring",[573,574,575,576,577,578],"cognitive impairment","cognitive impairment, mild","cognitive impairment, progressive","anesthesia","anesthesia brain monitoring","anesthesia depth monitoring","2026-05-04",{"date":523,"type":48},{"date":47,"type":21},{"date":583,"type":21},"2028-03",{"name":54,"class":55},{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":65,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":592,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":594,"conditions":595,"keywords":597,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":600,"startDateStruct":601,"completionDateStruct":602,"leadSponsor":604,"locationsCount":56},"100626045","secondary-care-colorectal-cancer-pathway-review-100626045","NCT07430527","Secondary Care Colorectal Cancer Pathway Review","A Retrospective Review of the Secondary-care Colorectal Cancer Pathway Within NHS Lothian: An Evaluation of 3 Years of Pathway Performance","Inclusion Criteria:\n\nPatients managed within the NHS Lothian CRC USoC\u002Furgent pathway (including urgent referrals) due to 'red-flag' symptoms concerning of CRC from April 2022 to August 2025.\n\nExclusion Criteria:\n\n* Under the age of 18.\n* History of inflammatory bowel disease.\n* Under polyp surveillance.\n* Previous diagnosis of CRC.",{"count":593,"type":21},25000,"Bowel cancer (colorectal cancer) is the 4th most common cancer in Scotland. Approximately 4,000 cases are diagnosed annually. Cancer-related deaths in Scotland are higher than other UK nations. Improving the early detection of bowel cancer, and therefore survival, is important.\n\nThe majority of bowel cancers are diagnosed within secondary-care (colorectal surgery unit). Upon GP referral to secondary-care, patients provide stool samples which are analysed for microscopic blood (FIT; faecal immunohistochemical test). Patients with a single positive result are more likely to have bowel cancer (0.2% risk if no blood detected, but 8.4% if detected). A positive test triggers further investigation, either CT scan or colonoscopy depending on the result. Currently, colonoscopy and radiology services throughout Scotland are under significant pressure causing delays.\n\nOnly 2% of patients referred to secondary-care are diagnosed with bowel cancer, and most colonoscopies performed do not yield significant findings. We have shown that performing two repeated FITs upon referral improves cancer pickup rate (sensitivity) and reduces missed cancers. We successfully implemented this in NHS Lothian and contributed to national guidelines.\n\nThis study will undertake a comprehensive retrospective review of the double-FIT urgent suspicion of bowel cancer pathway within NHS Lothian, from April 2022 (date of pathway inception) to August 2025, including around 25,000 patients that have been managed through the pathway. We will calculate key performance indicators and diagnostic accuracy of the pathway. Health economic analysis will determine cost-per-diagnosis. Risk factors for bowel cancer in this patient cohort will be identified to develop a support tool for primary and secondary-care. These results will be used to develop a future pathway to optimise pathway efficiency and cancer detection.",[596],"Colorectal Cancer (Diagnosis)",[598,599],"Faecal immunohistochemical test","FIT",{"date":523,"type":48},{"date":45,"type":21},{"date":603,"type":21},"2030-08-31",{"name":54,"class":55},{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":69,"phases":613,"briefSummary":614,"conditions":615,"keywords":4,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":623,"locationsCount":4},"100612552","optimizing-patient-treatment-with-epa-enriched-nutrition-a-randomised-control-trial-100612552","NCT07255066","Optimizing Patient Treatment With EPA-enriched Nutrition, a Randomised Control Trial","OPT-EPA","Inclusion Criteria:\n\n* Participants with stage III-IV lung and\u002For colorectal cancer undergoing systemic anti-cancer treatment (SACT) or starting SACT within the next 4 weeks \\*with non-curative intent\n* Participants aged 18 or older\n* Participants at nutritional risk defined as a BMI \\\u003C20 kg\u002Fm2 and\u002For weight loss between 5-10% in the previous 6 months\\*\\*\n* Participants with systemic inflammation within 28 days of screening (e.g. CRP \\>10 mg\u002FdL)\n* Participants with an ECOG-PS\\*\\*\\* score of 0, 1 or 2\n* Participants willing and able to give written informed consent\n\nExclusion Criteria:\n\n* Participants with a recent history of tumour resection (within 12 months)\n* Participants who have lost \\>10% body weight in the previous 6 months before baseline - observed or participant reported.\n* Participants with severe renal or hepatic failure or an intolerance to any of the ingredients of the study product\n* Participants who are using dietary counselling, ONS or any form of artificial feeding at the time of recruitment\n* Unable to adhere to either arm of the trial and appropriate requirements\n* Contraindication to ONS including a lactose intolerance\n* Females who are pregnant or of childbearing potential and not using adequate contraception",{"count":316,"type":21},[71],"Malnutrition is a common and serious issue for people living with cancer. Many cancer patients experience weight loss, muscle weakness, and poor quality of life due to malnutrition. This can also reduce the success of cancer treatments, increase hospital visits, and add emotional distress for both patients and their loved ones.\n\nTreating malnutrition through good nutritional care is increasingly recognised as an important part of cancer treatment. Leading experts recommend that all cancer patients be checked for signs of malnutrition and given personalised nutrition plans when necessary. While dietary counselling and oral nutritional supplements (ONS) are often used to help patients, there is still a need for better evidence to show how well these interventions work.\n\nA key factor contributing to malnutrition in cancer patients is inflammation. Omega-3 fatty acids, (like those found in oily fish) are known for their anti-inflammatory properties. Some studies suggest that omega-3s may help cancer patients by reducing inflammation, keeping muscles strong, improving appetite, and enhancing overall well-being.\n\nThe OPT-EPA study will investigate whether a nutritional drink, called Fortimel Forticare Sensations (FFS), can improve nutritional status in patients with lung or colorectal cancer who are at risk of malnutrition. This drink is enriched with omega-3 fatty acids (Eicosapentanoic acid (EPA) and Docosahexaenoic acid (DHA)) and provides a high amount of protein and calories in a small volume, making it easier to consume, especially for patients with taste changes.\n\nIn this study, participants will be divided into two groups. The experimental group will receive dietary counselling and standard care along with FFS, the omega-3-enriched nutritional drink, while the other (control) group will receive dietary counselling and standard care, with supplements provided only if clinically necessary. Researchers will evaluate the impact on patients' nutritional status, body weight, muscle, inflammation levels, and quality of life.\n\nThrough the OPT-EPA study, researchers hope to gain clearer insights into whether omega-3-containing supplements can provide meaningful benefits for cancer patients. Ultimately, this could help improve the quality of care and outcomes for people facing cancer-related malnutrition.",[616,365,617],"Malnutrition (Calorie)","Lung Cancer","2026-05-01",{"date":579,"type":48},{"date":621,"type":21},"2026-06",{"date":233,"type":21},{"name":54,"class":55},{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":630,"eligibilityCriteria":631,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":632,"enrollmentInfo":633,"targetDuration":4,"studyType":69,"phases":635,"briefSummary":636,"conditions":637,"keywords":639,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":641,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":647,"locationsCount":56},"100539817","fatigue-in-lupus-intervention-programmes-flip-100539817","NCT06308770","Fatigue in Lupus Intervention Programmes (FLIP)","Fatigue in Lupus Intervention Programmes (FLIP): A Randomised Controlled Trial Investigating the Effectiveness of Fatigue Management in Systemic Lupus Erythematosus","FLIP","Inclusion Criteria:\n\n1. Have a confirmed SLE Diagnosis\n2. Be over 18 at time of consent\n3. Report fatigue to be a chronic problem in the last 4 weeks with a VAS fatigue impact ≥ 6, based on a scale of 1 ( no fatigue impact on quality of life ) to 10 (severe impact of fatigue on quality of life).\\[20\\]\n4. Agree to online consent, complete questionnaires and be randomised to standard care or group intervention programme via secure server (REDCap).\n5. Not have taken part in a group fatigue or pain management programme in the past 5 years.\n6. Have the ability to read and converse in English competently\n7. Have access to a computer\u002FSmartphone\u002FTablet for internet and audio\u002Fvideo access.\n8. Be able to or willing to learn to use an NHS approved platform.\n9. Be willing to provide a telephone, postal address and email address for communication related to the FLIP trial.\n\nExclusion Criteria:\n\n1. They are unable to understand English sufficiently to attend a live online group programme. Facilitators and other group members will most likely only speak English.\n2. They are unable to provide confirmation of eligibility, complete online informed consent or questionnaires\n3. They are currently participating in an interventional trial","85 Years",{"count":634,"type":21},90,[71],"Systemic Lupus Erythematosus (SLE) is an autoimmune rheumatic disease. Patients report that fatigue has a significant impact on their quality of life but is often not discussed in healthcare settings. Fatigue is more prevalent in SLE than other Rheumatic diseases. Management across the NHS is very variable ranging from a booklet to one to one appointments or, less often, a group intervention. Previous studies in other Rheumatic diseases have shown that a group cognitive behavioural approach can be effective in helping patients manage their fatigue. The COVID-19 pandemic changed the way healthcare is delivered in the NHS . Healthcare professionals had to find alternate solutions e.g. Virtual appointments.\n\nOur study aims to establish whether a virtual group Fatigue Management Programme and a fatigue booklet (Versus Arthritis and Lupus UK) is more effective at reducing the impact of fatigue in SLE participants than the fatigue booklet alone.\n\nThe investigators will also compare a shortened 4-week to the standard 7-week programme to lessen the time commitment for participants and potentially reduce waiting times.The investigators will measure the effectiveness of the interventions through the use of Patient Reported Outcome Measures (PROMs) at several intervals whilst the participant is enrolled in the study.The pilot study will run in a single site in Edinburgh. The investigators aim to find a manageable, cost effective solution for the NHS and patients to address this frequently unmet need.",[638],"Systemic Lupus Erythematosus",[640],"Fatigue management",{"date":642,"type":48},"2026-05-07",{"date":644,"type":48},"2024-04-08",{"date":646,"type":21},"2027-09",{"name":54,"class":55},""]